COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital

Assiut University433 enrolled

Overview

We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19. All patients with COVID-19 associated Mucormycosis (CAM) admitted to Assuit University Hospital between March 1, 2021, and July 30, 2021, were included in this study. The patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with COVID-19.

Study Type

OBSERVATIONAL

Enrollment

433

Conditions

Mucormycosis

Interventions

antiviral, surgicalCOMBINATION_PRODUCT

surgical debridment

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria:We recruited all cases admitted to Assuit University Hospital for the management of COVID-19 and/or associated complications between March 1, 2021, and July 30, 2021, specifically those with probable mucormycosis based on clinical condition. At various times, internists, intensivists, neurologists, and otolaryngologists were among the specialists who assessed and treated them. Clinical; radiological and histopathological confirmed cases of mucormycosis with coexisting or previous history of COVID-19 were included in this study. \- Exclusion Criteria:Participants with fungal infections other than mucormycosis or without a confirmed diagnosis of COVID-19 (or serological evidence of preceding COVID-19) were excluded. \-

Locations (1)

Marwa Abdelrady

Asyut, Egypt

Outcomes

Primary Outcomes

incidence of covid19 associated mucor

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.